Clinical Trial

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2028-12-31 -> 2028-07-31 2026-04-23
Trial Details
NCT Number NCT07085039
Lead Sponsor University of Pennsylvania
Collaborators: Incyte Corporation, National Heart, Lung, and Blood Institute (NHLBI)
Conditions Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Enrollment 14 participants
Start Date 2025-12-18
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-22